Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: russo tdb. Crit Rev Oncol Hematol. 2022 Feb;170:103597. doi: 10.1016/j.critrevonc.2022.103597. Epub 2022 Jan 13. Crit Rev Oncol Hematol. 2022. PMID: 35033663 Review.
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Fanale D, Pivetti A, Cancelliere D, Spera A, Bono M, Fiorino A, Pedone E, Barraco N, Brando C, Perez A, Guarneri MF, Russo TDB, Vieni S, Guarneri G, Russo A, Bazan V. Fanale D, et al. Among authors: russo tdb. Crit Rev Oncol Hematol. 2022 Apr;172:103626. doi: 10.1016/j.critrevonc.2022.103626. Epub 2022 Feb 10. Crit Rev Oncol Hematol. 2022. PMID: 35150867 Review.
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Gristina V, La Mantia M, Peri M, Iacono F, Barraco N, Perez A, Viscardi G, Cutaia S, Russo TDB, Anwar Z, Incorvaia L, Fulfaro F, Vieni S, Pantuso G, Graceffa G, Russo A, Galvano A, Bazan V. Gristina V, et al. Among authors: russo tdb. Crit Rev Oncol Hematol. 2023 Feb;182:103899. doi: 10.1016/j.critrevonc.2022.103899. Epub 2022 Dec 31. Crit Rev Oncol Hematol. 2023. PMID: 36596401 Free article. Review.
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
Fanale D, Corsini LR, Bono M, Randazzo U, Barraco N, Brando C, Cancelliere D, Contino S, Giurintano A, Magrin L, Pedone E, Perez A, Piraino P, Pivetti A, Giovanni ED, Russo TDB, Prestifilippo O, Gennusa V, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: russo tdb. Crit Rev Oncol Hematol. 2024 Jan;193:104220. doi: 10.1016/j.critrevonc.2023.104220. Epub 2023 Nov 29. Crit Rev Oncol Hematol. 2024. PMID: 38036154 Review.
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer.
Gottardo A, Russo TDB, Perez A, Bono M, Di Giovanni E, Di Marco E, Siino R, Bannera CF, Mujacic C, Vitale MC, Contino S, Iannì G, Busuito G, Iacono F, Incorvaia L, Badalamenti G, Galvano A, Russo A, Bazan V, Gristina V. Gottardo A, et al. Among authors: russo tdb. Cytopathology. 2024 Nov;35(6):664-670. doi: 10.1111/cyt.13396. Epub 2024 Jun 1. Cytopathology. 2024. PMID: 38822635 Review.
Scientific Communication and oncology - "The bridge between knowledge and patients".
Galvano A, Gottardo A, Gristina V, Fanale D, Corsini LR, Pavone C, Bazan Russo TD, Di Giovanni E, Iannì G, Randazzo U, Iacono F, Perez A, Brando C, Bono M, Bazan V, Incorvaia L, Badalamenti G, Cinieri S, Boldrini M, Berardi R, Russo A. Galvano A, et al. Crit Rev Oncol Hematol. 2024 Dec;204:104531. doi: 10.1016/j.critrevonc.2024.104531. Epub 2024 Oct 18. Crit Rev Oncol Hematol. 2024. PMID: 39427840 Free article. Review.